Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: wvalx who wrote (21664)	5/5/1999 6:09:00 PM
From: VLAD	Respond to of 23519

Do you remember last July when Charlie O upgraded to a buy with a 12 month target of 20 when the stock was trading at 6? The analysts covering this stock have all been dead wrong on the way down and they probably will be dead wrong on the way up. Other than an announcement for a domestic partner, what Vivus needs most is to get the ball rolling on the female SD cream. It will beat an oral hands down. It will be something the media will just love to talk about. Free press for us.

To: wvalx who wrote (21664)	5/5/1999 6:29:00 PM
From: Mkilloran	Respond to of 23519

wvalx....Vivus is on course to prove it's self to Wall Street analyst. As the following events unfold Vivus will gain the respect of Wall Street Analyst and will be rewarded with upgrades and increased coverage. Major items that will effect analyst upgrades are: USA partner Japan Partner Other news items that will effect analyst upgrades are: positive news that Female SD, Premature Ejaculation or Incontinence drugs can be marketed in a short timeframe (1-3) years. continued positive earnings results and maintaining cost controls for the 2nd qtr, 3rd qtr, 4th qtr completion of Phase III trials on Alibra and submission for NDA approval of milestone countries Spain, Italy, China in 2nd and 3rd qtrs successful launch reports from Astra/Zeneca and Janssen negotiated distribution rights for Alibra with partners for worldwide sales inplace prior to the approval of Alibra by FDA and MCA